CompletedPhase 1NCT03428347
An Open Study of the Safety and Pharmacokinetics of a Medicinal Product for Emergency Prevention of Ebola
Studying Ebola hemorrhagic fever
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- Principal Investigator
- Dmitry Lyoznov, MD, PhDResearch Institute of Influenza, Sankt-Peterburg, Russian Federation
- Intervention
- GamEMab(biological)
- Enrollment
- 25 enrolled
- Eligibility
- 18-45 years · All sexes
- Timeline
- 2018 – 2018
Study locations (1)
- Research Institute of Influenza, Saint Petersburg, Russia
Collaborators
Research Institute of Influenza, Sankt-Peterburg, Russian Federation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03428347 on ClinicalTrials.govOther trials for Ebola hemorrhagic fever
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT05992480REVIVE (Response to the Ebola Virus Vaccine)Tulane University
- ACTIVE NOT RECRUITINGPHASE2NCT06803342A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy AdultsAlbert B. Sabin Vaccine Institute
- RECRUITINGPHASE3NCT06126822Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination with the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRCInstitute of Tropical Medicine, Belgium
- ACTIVE NOT RECRUITINGPHASE2NCT06100913Immunology of Ebola VaccineEmory University